# SHR-8068 Combined With Adbelizumab and BP102 in the Treatment of Advanced Colorectal Cancer

> **NCT06373133** · PHASE1,PHASE2 · NOT_YET_RECRUITING · sponsor: **West China Hospital** · enrollment: 36 (estimated)

## Conditions studied

- Colorectal Cancer

## Interventions

- **DRUG:** SHR-8068
- **DRUG:** Adebrelimab
- **DRUG:** BP102

## Key facts

- **NCT ID:** NCT06373133
- **Lead sponsor:** West China Hospital
- **Sponsor class:** OTHER
- **Phase:** PHASE1,PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** NOT_YET_RECRUITING
- **Start date:** 2024-05-01
- **Primary completion:** 2026-11-01
- **Final completion:** 2026-11-01
- **Target enrollment:** 36 (ESTIMATED)
- **Last updated:** 2024-04-18


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT06373133

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT06373133, "SHR-8068 Combined With Adbelizumab and BP102 in the Treatment of Advanced Colorectal Cancer". Retrieved via AI Analytics 2026-06-02 from https://api.ai-analytics.org/clinical/NCT06373133. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*